Logo

Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men

Share this

Astellas' Xtandi (enzalutamide) Receives NMPA's Approval for Metastatic Castration-Resistant Prostate Cancer in Men

Shots:

  • The approval is based on P-III Asian PREVAIL study assessing Xtandi (160mg/day) vs PBO + GnRH therapy or after bilateral orchiectomy in patients with progressive metastatic mCRPC who had disease progression despite ADT and a single dose PK study in 200 Chinese patients
  • The P-III Asian PREVAIL study results: reduction in risk of PSA progression; median time to PSA progression (8.31 vs 2.86mos.); reduction in radiographic disease progression; improvement in OS; 67% reduction in the risk of death
  • Xtandi is a nonsteroidal antiandrogen medication- indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer and nonmetastatic castration-resistant prostate cancer

Click here to­ read full press release/ article 

Ref: Astellas | Image:Astellas


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions